Skip to content
OpenCapital
Get started

Bausch + Lomb BLCO Pharmaceuticals — Selling, general and administrative (Note 4)

Other segment segments

Vision Care
$228M+3.2%
Surgical
$73M0.0%

Similar metrics at other companies

Baxter International logo
BAXPharmaceuticals — Selling, general and administrative expenses
$102M-1.0%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Selling and other commercial expenses
$313.6M+30.1%
Abbott logo
ABTEstablished Pharmaceuticals — Selling, general, and administrative
$376M+7.1%
Pfizer logo
PFEBiopharma — Selling, informational and administrative expenses
$2.13B-2.5%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — General and administrative expenses
$180.1M+16.0%
BrightSpring Health Services, Inc. logo
BTSGPharmacy Solutions — Selling General And Administrative Expense From Reportable
$157.03M+35.7%

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4)?
Bausch + Lomb (BLCO) reported pharmaceuticals — selling, general and administrative (note 4) of $138M in Q1 2026.
How has Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4) changed year-over-year?
Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4) decreased by 9.8% year-over-year, from $153M to $138M.
What is the long-term trend for Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4)?
Over 3 years (2022 to 2025), Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4) has grown at a 35.5% compound annual growth rate (CAGR), from $230M to $572M.
What does pharmaceuticals — selling, general and administrative (note 4) mean?
Includes the indirect costs associated with operating the pharmaceutical segment, such as marketing, sales force compensation, and administrative overhead. Monitoring this metric helps assess the operational efficiency and the cost-to-serve ratio of the segment's commercial activities.